Segments (Tables)

3 Months Ended

Mar. 31, 2021

Summary of Segment Profit

a. Segment information:

	Three months ended March 31,
	2021
	North America			Europe		International Markets
	(U.S. $ in millions)
Revenues	$	1,989		$	1,214	$	490
Gross profit		1,074			688		260
R&D expenses		160			66		18
S&M expenses		229			214		96
G&A expenses		111			70		26
Other income		(3	)		§		(2	)
Segment profit	$	577		$	338	$	122

§ Represents an amount less than $1 million.

	Three months ended March 31,
	2020
	North America			Europe			International Markets
	(U.S. $ in millions)
Revenues	$	2,082		$	1,402		$	565
Gross profit		1,062			823			305
R&D expenses		146			55			15
S&M expenses		251			202			106
G&A expenses		118			66			34
Other income		(2	)		(1	)		(6	)
Segment profit	$	550		$	502		$	156

Schedule Of Consolidated Income Before Income Tax

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March 31, 2021 and 2020: 

	Three months ended
	March 31,
	2021		2020
	(U.S. $ in millions)
North America profit	$	577	$	550
Europe profit		338		502
International Markets profit		122		156
Total reportable segments profit		1,036		1,208
Profit of other activities		41		36
Total segments profit		1,077		1,244
Amounts not allocated to segments:
Amortization		242		258
Other assets impairments, restructuring and other items		137		121
Intangible asset impairments		79		649
Legal settlements and loss contingencies		104		(25	)
Other unallocated amounts		82		49
Consolidated operating income (loss)		434		191
Financial expenses, net		290		224
Consolidated income (loss) before income taxes	$	144	$	(33	)

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three months ended March 31, 2021 and 2020:

North America	Three months ended March 31,
	2021		2020
	(U.S. $ in millions)
Generic products	$	1,053	$	952
AJOVY		31		29
AUSTEDO		146		122
BENDEKA/TREANDA		91		105
COPAXONE		164		198
ProAir*		54		59
Anda		289		426
Other		161		191
Total	$	1,989	$	2,082

* Does not include revenues from ProAir authorized generic, which are included under generic products.

Europe	Three months ended March 31,
	2021		2020
	(U.S. $ in millions)
Generic products	$	865	$	1,032
AJOVY		16		4
COPAXONE		100		109
Respiratory products		93		106
Other		140		151
Total	$	1,214	$	1,402

International markets	Three months ended March 31,
	2021		2020
	(U.S. $ in millions)
Generic products	$	392	$	449
COPAXONE		12		12
Other		86		104
Total	$	490	$	565